Position statement on the use of bortezomib in multiple myeloma

被引:7
|
作者
Morgan, G. J. [1 ]
Davies, F. E. [1 ]
Cavenagh, J. D. [2 ]
Jackson, G. H. [3 ]
机构
[1] Royal Marsden Hosp, Haemato Oncol Unit, London SW3 6JJ, England
[2] St Bartholomews & Royal London Hosp, Dept Haematol, London, England
[3] Royal Victoria Hosp, Dept Haematol, Newcastle, NSW, Australia
关键词
myeloma; bortezomib; proteasome inhibition; relapse therapy;
D O I
10.1111/j.1751-553X.2007.01020.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bortezomib (Velcade (TM)) is a boron containing molecule which reversibly inhibits the proteasome, an intracellular organelle which is central to the breakdown of ubiquinated proteins and consequently crucial for normal cellular homeostasis. Phase II clinical trials demonstrate it is effective for the treatment of relapsed refractory myeloma, and a phase III trial comparing bortezomib to dexamethasone in second/third line treatment showed superiority in progression free and overall survival. It is administered intravenously in the outpatient setting on days 1, 4, 8 and 11 of a 21-day cycle and regular monitoring for side effects is essential. It is currently approved for the treatment of multiple myeloma patients who have received at least one prior therapy and who have already undergone or are unsuitable for transplantation. Given the strength of this data the UK Myeloma Forum and British Committee for Standards in Haematology believe that bortezomib should be available for prescription by UK haematologists according to its licensed indication in patients with relapsed myeloma.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [31] USE OF MAINTENANCE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE (VD) IN ADVANCED MULTIPLE MYELOMA
    Benevolo, G.
    Larocca, A.
    Pregno, P.
    Gay, F.
    Botto, B.
    Gentile, C.
    Frairia, C.
    Evangelista, A.
    Morabito, F.
    Palumbo, A.
    Vitolo, U.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 160 - 160
  • [32] Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma
    Van Keer, Jan
    Delforge, Michel
    Dierickx, Daan
    Peerlinck, Kathelijne
    Lerut, Evelyne
    Sprangers, Ben
    CASE REPORTS IN HEMATOLOGY, 2016, 2016
  • [34] Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma
    Froehlich, Karen
    Holle, Julia U.
    Aries, Peer M.
    Gross, Wolfgang L.
    Moosig, Frank
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (07) : 1344 - U195
  • [35] Bortezomib in Multiple Myeloma: A Practice Guideline
    Kouroukis, C. T.
    Baldassarre, F. G.
    Haynes, A. E.
    Imrie, K.
    Reece, D. E.
    Cheung, M. C.
    CLINICAL ONCOLOGY, 2014, 26 (02) : 110 - 119
  • [36] Bortezomib dosing in relapsed multiple myeloma
    Jagannath, Sundar
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (02): : 101 - 102
  • [37] Overcoming bortezomib resistance in multiple myeloma
    Murray, Megan Y.
    Auger, Martin J.
    Bowles, Kristian M.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2014, 42 : 804 - 808
  • [38] Bortezomib for previously untreated multiple myeloma
    de la Rubia, Javier
    Roig, Monica
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (04) : 381 - 398
  • [39] The safety of bortezomib for the treatment of multiple myeloma
    Seval, Guldane Cengiz
    Beksac, Meral
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (09) : 953 - 962
  • [40] Cutaneous involvement in multiple myeloma and bortezomib
    Siniscalchi, A.
    Fratoni, S.
    Santeusanio, G.
    Del Poeta, G.
    de Fabritiis, P.
    Caravita, T.
    ANNALS OF HEMATOLOGY, 2009, 88 (11) : 1137 - 1139